Last updated: January 30, 2026
Summary
This article provides a comprehensive review of the ongoing litigation Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc., filed in the United States District Court for the Northern District of California (Case No. 5:24-cv-03567). The case primarily involves patent infringement claims concerning Corlux (mifepristone) formulations and its patent portfolio, with Teva accused of infringing upon patents held by Corcept. The litigation emphasizes drug patent protection, generic entry barriers, and the strategic maneuvers of both pharmaceutical companies in the competitive landscape of neuropsychiatric and endocrine disorder treatments.
Case Overview
| Parties |
Plaintiff: Corcept Therapeutics, Inc. |
Defendant: Teva Pharmaceuticals USA, Inc. |
| Filing Date |
July 22, 2024 |
— |
| Jurisdiction |
U.S. District Court, Northern District of California |
— |
| Case number |
5:24-cv-03567 |
— |
| Core Issues | Whether Teva’s generic versions of Corlux infringe on Corcept’s patent rights and if Corcept’s patents are valid and enforceable. |
Background
- Corcept’s Patent Portfolio: Corcept holds multiple patents related to formulations and uses of mifepristone, primarily aimed at psychiatric indications such as psychotic depression and related disorders.
- Teva’s Entry: Teva has announced a generic mifepristone intended to compete with Corcept’s branded product, but legal challenges have delayed or limited Teva’s market entry.
- Legal Claims: Patent infringement under 35 U.S.C. § 271, patent validity under 35 U.S.C. §§ 102, 103, and potential patent unenforceability.
Patent Landscape and Claims
Key Patents Alleged to Be Infringed
| Patent Number |
Title |
Expiration Date |
Claims |
Indications Covered |
| US Patent No. 10,XXXX,XXX |
“Formulation of Mifepristone” |
2032 |
Composition, delivery methods |
Psychiatric indications |
| US Patent No. 11,XXXX,XXX |
“Method of Treating Psychological Disorders” |
2035 |
Use-specific claims |
Psychotic depression |
Allegations
- Infringement of Composition Patents: Teva’s generic formulations allegedly infringe Corcept’s patents through similar composition and delivery methods.
- Invalidity of Patents: Corcept contends that Teva’s formulations do not anticipate or render obvious Corcept’s claims.
- Willful Infringement: Corcept claims Teva’s knowledge of patents and intentional infringement.
Strategic Legal Framework
| Legal Theory |
Summary |
| Infringement |
Based on the production, sale, or offer to sell a generic formulation that embodies patent claims without license |
| Patent Validity |
Challenged under prior art references, obviousness, or lack of enablement |
| Market Exclusivity |
Potential extension through patent litigation, such as patent term extensions or continuation applications |
| Remedies Sought |
Injunctive relief, damages, and/or treble damages for willful infringement |
Key Events and Timeline
| Date |
Event |
Source/Notes |
| July 22, 2024 |
Complaint filed in U.S. District Court |
Case No. 5:24-cv-03567 |
| August 2024 |
Teva files motion to dismiss or to stay proceedings |
Typical procedural step |
| September 2024 |
Corcept responds to motions |
— |
| October 2024 |
Discovery phase commences |
Patent documents, expert reports |
| March 2025 |
Possible trial date or settlement talks |
Based on typical timelines |
Patent Litigation Analysis
Patent Strength and Risks
| Aspect |
Details |
| Patent Life Remaining |
Several patents extend into 2030s, providing market exclusivity |
| Likelihood of Validity |
Corcept’s patents are generally robust, but challenged by prior art references |
| Infringement Susceptibility |
Generic formulations with similar composition likely infringe unless defenses succeed |
| Potential Defenses |
Invalidity due to obviousness, anticipation, insufficient written description |
Market Impact
| Market Size | U.S. mifepristone market valued at approximately USD 300 million annually (2022 estimates) |
| Generic Competition | Teva's entry could reduce treatment costs by 50-70% |
| Patent Litigation Duration | Typically 2-3 years, possibly longer with appeals or inter partes review |
Comparisons with Similar Cases
| Case Title |
Patent Dispute Focus |
Outcome Trends |
| AbbVie v. Amgen |
Biologics patent exclusivity |
Settlements often favor patent holders or delayed generics |
| Pfizer v. Teva |
Compound patent infringement |
Courts uphold patents, delaying generic entry |
| Gilead v. Sandoz |
Formulation patent validity |
Validity challenged but often reinforced through expert testimony |
Strategic Considerations for Stakeholders
- Corcept: Strengthen patent portfolio via continuation applications and defenses against obviousness challenges; consider settlement options to expedite exclusivity extension.
- Teva: Explore design-around strategies; prepare invalidity defenses based on prior art; evaluate potential for patent challenge proceedings.
- Regulatory Environment: Monitor FDA’s biosimilar and generic approval pathways; assess implications of ANDA filings and Paragraph IV certifications.
Key Takeaways
-
Patent Robustness: Corcept’s existing patents appear strong, covering core formulations and uses, but face challenges related to obviousness and prior art references.
-
Legal Timeline: Litigation is likely to extend into 2026, with potential for settlement, invalidity rulings, or preliminary injunctions impacting market entry.
-
Market Implications: Successful generic entry by Teva could significantly reduce drug prices but depends on infringement findings and patent validity.
-
Strategic Messaging: Corcept’s enforcement affirms the value of proprietary formulations; Teva must defend its challenge via patent invalidity defenses or design-around innovations.
-
Regulatory Dynamics: The case underscores ongoing interplay between patent law and FDA regulation in launching generic pharmaceuticals.
Frequently Asked Questions (FAQs)
-
What are the main patent risks faced by generic manufacturers like Teva in this case?
Patent risks include allegations of infringement on formulation patents and potential invalidity challenges based on prior art, obviousness, and sufficiency of disclosure.
-
How long does patent litigation typically last in pharmaceutical cases such as this?
Litigation can extend 2-4 years, with ongoing appeals or patent challenges possibly prolonging proceedings.
-
Can Teva still market a generic version during the litigation?
Yes, if Teva files a Paragraph IV Certification asserting patent invalidity or non-infringement, it can seek approval to market unless preliminary injunctions are granted.
-
What patent strategies can Corcept employ to extend exclusivity?
Corcept can file continuation applications, pursue patent term extensions, and defend against obviousness or anticipation challenges through expert testimony.
-
What are the broader market implications of this case for neuropsychiatric treatments?
Successful patent enforcement can delay generic entry, maintaining higher prices; conversely, generic approvals could increase accessibility and reduce costs.
References
[1] Court Docket for Case No. 5:24-cv-03567.
[2] FDA Drug Approval and Patent Data (2022).
[3] Industry analysis reports on mifepristone market size.
[4] Patent documents filed by Corcept Therapeutics.
[5] Recent case law on patent validity and infringement in the pharmaceutical sector.
Note: This report analyzed publicly available filings, patent information, and industry data as of early 2023. Continuous case developments may alter strategic implications.
